Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.: Examining Key Revenue Metrics

Takeda vs. Lantheus: A Decade of Revenue Growth

__timestampLantheus Holdings, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20143016000001777824000000
Thursday, January 1, 20152934610001807378000000
Friday, January 1, 20163018530001732051000000
Sunday, January 1, 20173313780001770531000000
Monday, January 1, 20183433740002097224000000
Tuesday, January 1, 20193473370003291188000000
Wednesday, January 1, 20203394100003197812000000
Friday, January 1, 20214252080003569006000000
Saturday, January 1, 20229350610004027478000000
Sunday, January 1, 202312964290004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Unleashing the power of data

A Tale of Two Companies: Takeda vs. Lantheus

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and Lantheus Holdings, Inc. stand as intriguing case studies of growth and resilience. Over the past decade, Takeda has consistently demonstrated its dominance, with revenue figures soaring by approximately 140% from 2014 to 2023. This Japanese giant, with its strategic acquisitions and robust pipeline, has cemented its position as a leader in the global market.

Conversely, Lantheus Holdings, Inc., though smaller in scale, has shown remarkable growth, with revenues increasing by over 330% in the same period. This American company has carved a niche in the diagnostic imaging sector, showcasing its agility and innovation.

While Takeda's revenue in 2023 reached an impressive 4.26 trillion, Lantheus's growth trajectory is noteworthy, reflecting the dynamic nature of the pharmaceutical industry. Missing data for 2024 suggests a potential for further analysis and insights.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025